FRI0180 OFF-LABEL USE OF RITUXIMAB IN RHEUMATIC DISEASES, A SWISS TERTIARY CENTRE EXPERIENCE

Abstract

Background: Rituximab (RTX), a monoclonal antibody targeting CD20, is licenced for the treatment of rheumatoid arthritis (RA) for many years and more recently for ANCA-associated vasculitis. RTX is frequently used off-label to treat other auto-immune diseases (AID), especially connective tissue diseases (CTD). There are no published data about off-label use of RTX in AID in Switzerland. Objectives: To describe off-label use of RTX in a real-life setting, when treating AID. Methods: Retrospective cohort study of all patients treated with RTX in the Rheumatology Department between 2005 and 2017. Clinical efficacy of RTX after 12 and 24 months of treatment was evaluated with a semi-quantitative scale (no response (NR), partial (PR) and complete response (CR)). RTX discontinuation rate was also analysed using Kaplan-Meier method and log rank test to evaluate the difference between survival curves. Adverse events (AE), serious AE (SAE) were included in the safety analysis. Occurrences of hypogammaglobulinemia and anti-rituximab antibodies (ADA) were also reported. Results: 178 patients treated with RTX could be identified: 28% for CTD, 63% for RA and 10% for other AID. Rituximab was used off-label in 73% of the patients according to official Swiss indications. No significant differences in terms of clinical response were observed in off-label indication after 12 months (NR: 15%/13%, PR:48%/52%, CR:37%/35%, n=108/31) and 24 months (NR:13%/9%, PR:37%/35%, CR:51%/57%, n=79/23) of treatment when compared with prescriptions following official Swiss indications, respectively. RTX discontinuation rate (HR 1.03 95% CI 0.71-1.49) was also similar between both groups. Clinical response after RTX treatment did not differ significantly between patients with CTD and RA after 12 months (NR:10%/12%, PR:50%/52%, CR:40%/36%, n=42/n=84) and 24 months (NR:7%/9%, PR:32%/44%, CR:61%/47%, n=28/n=64), respectively. Detailed results are available in Table 1. Survival curves of rituximab treatment from CTD group closely matched that from RA group (HR 0.96 95% CI 0.65-1.44). Causes of RTX treatment discontinuation in patients with CTD (n=27) and RA (n=72) consisted of lack of efficiency (63%/56%), adverse event (19%/35%) and remission (19%/10%), respectively. SAE (n=113) occurred in 33% of the patients and consisted mainly of infectious SAE (43%) and perfusion-related AE (6%). 6 patients died during RTX treatment. Low IgG levels were observed in 34% (50/149) of the patients graded as mild (20%), moderate (11%) or severe (3%). The nadir of IgG levels occurred after 4.5(3.5) years (mean (SD)) of RTX treatment. ADA were observed in 6/51 patients. Conclusion: Off-label prescription of rituximab to treat AID was frequent. RTX discontinuation rate was comparable in patients treated for CTD and RA in our population. Disclosure of Interests: Alexandre Dumusc: None declared, Thomas Huegle Grant/research support from: AbbVie, Lilly, Novartis and Pfizer, Speakers bureau: AbbVie, Lilly, Novartis and Pfizer, Pascal Zufferey: None declared